According to the Centers for Disease Control and Prevention (CDC), an estimated 25.8 million people in the United States have diabetes. Diabetes is the leading cause of kidney failure, nontraumatic lower-limb amputation, and new cases of blindness. Although health plans are mostly eager to offer wide formulary access to therapies for diabetes as a result of this huge need, greater inter-brand competition both within and across drug classes and the generic entry of several key brands will allow health plans more opportunities to design formularies for type 2 diabetes with a focus on drug cost.


Related Reports

Formulary Advantages in Atrial Fibrillation: How Will MCO Size Affect the Design of Factor Xa Formularies?

In the coming years, atrial fibrillation (AF) patients will increasingly have more choice for anticoagulation therapy. Although Boehringer Ingelheim’s Pradaxa (dabigatran etexilate) and emerging facto...

View Details

Formulary Advantages in Asthma and COPD Therapies: Formulary Advantages in Asthma and COPD Therapies - Abstract

The market for asthma and chronic obstructive pulmonary disease (COPD) has grown notably in recent years because of increasing prevalence and diagnosis rates for both conditions as well as the greater...

View Details

Formulary Advantages in Psychiatric Drugs: Medicare plans readily employ cost-sharing measures and formulary restrictions to direct early use of generics and preferred brands for psychiatry.

According to the National Institute of Mental Health, each year tens of millions of Americans are affected by mental illness. Although significant strides have been made toward understanding the patho...

View Details

Formulary Advantages in Immune Biologic Therapies: Health plans’ support for certain drug attributes drive formulary coverage for immune biologic brands

The market for immune biologics has grown increasingly crowded in recent years with the launches of newer brands such as Simponi, Cimzia, and Stelara looking to take share away from longer-marketed pr...

View Details